Clovis Oncology (CLVS) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
Clovis Oncology Announces Third Quarter 2017 Operating Results
November 1, 2017 4:05 PM EDTStrong third quarter of launch for Rubraca® (rucaparib) in U.S. with $16.8M reported in net sales An additional $4.4M in commercial value was provided as free drug through our patient assistance program Submission of a supplemental New Drug Application (sNDA) for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer completed in early October Comprehensive ARIEL3 dataset presented at the 2017 European Society for Medical Oncology Congress in Madrid and published in The Lancet demonstrated that rucaparib significantly... More
